This resistance can be reversed through gene amplification or pharmacological approaches aimed at restoring ferroptosis sensitivity, potentially offering new therapeutic strategies for chemotherapy-resistant HER2-positive breast cancer (22). This evidence concerns the gene ERBB2 and breast carcinoma.